@prefix nkg: .
@prefix nt: .
@prefix orcid: .
@prefix bl: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo;
a np:Nanopublication .
}
sub:assertion {
a bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Clozapine is not recommended for OCD due to poor evidence of efficacy [170]. In addition, several case reports and clinical studies support the association of clozapine with worsening or onset of obsessive-compulsive symptoms in patients with a psychotic disorder [171-176]. At least 20% of individuals treated with clozapine (and other antiserotonergic antipsychotics) would experience worsening or emergence of obsessive-compulsive symptoms [177], which are dose-related [178] and generally reversible upon discontinuation of clozapine treatment and switch to a different antipsychotic [179]";
bl:has_population_context sub:context;
bl:provided_by ;
bl:publications ;
bl:relation nkg:OffLabelIndication .
sub:context a bl:Cohort;
rdfs:label "adults" .
a bl:Drug .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-08-25T14:52:29.045065"^^xsd:dateTime .
}
sub:pubInfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "GsbY5Rbf6Gbvaiit2lQi84DcwIpIcxQg1AFco8HJT0BKmN2VqnPquPkYM9KgdePNBhe65iEH+k+zJjAeLnsqZdoNsCl55SrU56jJTiDFSld3kMbWYkyXoMrWYlLsyGSo8z9O9/MXAvNbpoRLYIsp+6P1gs2DqdM5mr/Q0Wf4ve8=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2021-08-25T14:52:29.045065"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-7641-6446;
nt:wasCreatedFromTemplate .
}